Your GLP Compliant Lab for drug discovery, pre-clinical and new product development. Unrivalled experience with natural product development serving the pharmaceutical nutraceutical and novel food markets
Our complementary expertise in pharmaceuticals and nutraceuticals allows us to work on a variety of projects.
Neuro Nature LDA, a Portuguese contract research organization with expertise in drug discovery, in-vivo and in-vitro preclinical studies, and pharmaceutical regulation. Our GLP-compliant laboratory ensures the highest standards of quality and accuracy.
In addition, we offer new product development for nutraceutical and food products, tailored to meet the unique needs of our clients.
Our lab is equipped to conduct Drug Discovery and Preclinical Research. We adhere to the highest standards to ensure the quality control, safety, and efficacy of the products we develop and test. We conduct Stability Studies, Efficacy Behavioural Models, and Comprehensive Toxicological data packages to support regulatory submissions to EFSA for Novel Food authorization; Health Canada for Natural Health Product approval; EMA herbal medicinal product submissions; and FDA botanical drug guidance.
Jagdeep Gill LLB (Hons), LLM (IP)
Managing Director, Neuro Nature LDA | Director, Albert Labs International Corp.
• Founded and scaled Bishop Sixth Sense, commercializing proprietary IP infringement detection software that orchestrated international investigations with Europol, Interpol, and PIPCU, protecting billions in corporate assets across EMEA while serving as Chairman of the Imaging Consumables Coalition of EMEA (ICCE) (1997–2009).
• Led transformational GDPR and AML compliance frameworks for multinational banking institutions at Ernst & Young (2018–2020), architecting enterprise-wide cybersecurity and regulatory risk mitigation solutions across international financial networks.
• Brings 30+ years converting complex regulatory challenges into competitive advantages—from anti-counterfeiting ecosystems to cutting-edge data protection infrastructures—with proven expertise in patent strategy, novel foods regulatory pathways (GRAS, EU Novel Foods, Belgium Dietary Supplements), and EU funding applications.
• Credentials: LLM Intellectual Property Laws (Queen Mary); LLB (Hons) Law (London School of Economics); Advanced Certificate in Anti-Money Laundering (Merit, ICA).
• Directly strengthens Albert Labs’ investment case by architecting HIPAA-compliant data governance frameworks for AI-driven mental health platforms, de-risking US and EU regulatory pathways for natural anxiolytics, and building robust patent portfolios—enhancing institutional partnerability and investor confidence in commercial readiness.
An expert Toxicologist and Pharmacologist, having authored more than 170 published peer reviewed 2021
He was included in the world’s top 2% of Scientists, which ranks the most highly cited scientists globally.
Senior Editor Psychoactives of MDPI Medical Journal
15+ years of management experience leading a team of medical writers and scientific communications specialists in regulatory, safety, market access, and health economics across a range of therapeutic areas
Dr. Hyder A. Khoja, Ph.D., is a biotech innovator with 22+ years spanning drug discovery, nutraceuticals, and psychedelics. A co-founder of InMed Pharmaceuticals and former CSO across multiple life science ventures, he has led extraction, standardization, and scale-up of plant/fungal bioactives, developed IP, and navigated regulatory pathways with EFSA/FDA/Health Canada alignment. He has advanced cannabinoid, kava, catuaba, and lion’s mane programs from lab to commercialization.
At Neuronature LDA, Dr. Khoja will drive the Anxiety Project from technical specs to pilot production—optimizing formulations, delivery systems, stability, toxicology, and preclinical efficacy—while integrating AI-driven analytics for QC and process design. His partnerships and fundraising track record accelerate translation to market.
Advisor, EU Funding and Market Development
Jagdeep Gill LLB (Hons), LLM (IP)
Managing Director, Neuro Nature LDA | Director, Albert Labs International Corp.
• Founded and scaled Bishop Sixth Sense, commercializing proprietary IP infringement detection software that orchestrated international investigations with Europol, Interpol, and PIPCU, protecting billions in corporate assets across EMEA while serving as Chairman of the Imaging Consumables Coalition of EMEA (ICCE) (1997–2009).
• Led transformational GDPR and AML compliance frameworks for multinational banking institutions at Ernst & Young (2018–2020), architecting enterprise-wide cybersecurity and regulatory risk mitigation solutions across international financial networks.
• Brings 30+ years converting complex regulatory challenges into competitive advantages—from anti-counterfeiting ecosystems to cutting-edge data protection infrastructures—with proven expertise in patent strategy, novel foods regulatory pathways (GRAS, EU Novel Foods, Belgium Dietary Supplements), and EU funding applications.
• Credentials: LLM Intellectual Property Laws (Queen Mary); LLB (Hons) Law (London School of Economics); Advanced Certificate in Anti-Money Laundering (Merit, ICA).
• Directly strengthens Albert Labs’ investment case by architecting HIPAA-compliant data governance frameworks for AI-driven mental health platforms, de-risking US and EU regulatory pathways for natural anxiolytics, and building robust patent portfolios—enhancing institutional partnerability and investor confidence in commercial readiness.
10+ years experience in medicinal mushrooms and botanical extraction, with contributions to neurodegenerative clinical trials and expertise in GLP systems
Co-founded Marygold Laboratories and ARextracts for botanical testing
Numair is a UK registered pharmacist and EU/UK QPPV. He has over a decade of experience in the production, quality assurance and pharmacovigilance of products. Numair has managed multiple disciplinary teams for companies holding over 30 UK Marketing Authorisations. He has worked extensively with the NHS in technical services, providing quality assurance and production expertise for Aseptic production units working under MS License. Numair has worked on manufacturing clinical trial products for the treatment of COVID-19 and Brain Tumours. He also formed part of the team that produced the first commercial batch in the UK for Gene Therapy product, Zolgensma: a life-saving drug worth £1.8 million that can enable mobility in babies and young children suffering from a rare genetic condition.
CESPU – Cooperativa de Ensino Superior Politécnico e Universitário, C.R.L. R. Central da Gandra 1317 4585 Gandra, Portugal
Neuro Nature, Unipessoal LDA Avenida Dom Carlos I, 103, R/C A 1200-648 Lisboa Portugal
